Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose LevelsEwa Lech‐Marańda, Jan Maciej Zaucha, Noemi Angelosanto et al.|Blood|2023Cited by 1
Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Adam Radzimierski et al.|Cancer Research|2025Cited by 1
Novel method of measurement of in vitro drug uptake in OATP1B3 overexpressing cells in the presence of dextranAnna Kowal-Chwast, Kamil Kuś, Nilesh Gaud et al.|Pharmacological Reports|2024Cited by 0